Simulations Plus Sets Date for Third Quarter Fiscal Year 2022 Earnings Release and Conference Call
06/21/2022 - 04:06 PM
Conference call to be on Wednesday, July 6, 2022 , at 5:00 PM ET
LANCASTER, Calif. --(BUSINESS WIRE)--
Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report financial results for the third quarter of fiscal year 2022, the period ended May 31, 2022 , after the close of the financial markets on Wednesday, July 6, 2022 .
The Company will host a conference call on July 6, 2022 , at 5:00 p.m. Eastern Time . All interested parties are invited to join the call by registering here or by calling 1-201-389-0879. Please join five to 10 minutes before the scheduled start time. The call will be simulcast live on the Internet, and the webcast will be available on the Investors page of the Simulations Plus website under Conference Calls & Presentations . A replay of the webcast will be available on the website approximately one hour following the call.
About Simulations Plus
Serving clients worldwide for 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supporting drug discovery, development, research, and regulatory submissions. We offer solutions that bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com . Follow us on LinkedIn | Twitter | YouTube .
Environmental, Social, and Governance (ESG)
We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our ESG Report .
View source version on businesswire.com : https://www.businesswire.com/news/home/20220621005410/en/
Simulations Plus Investor Relations
Renee Bouche
renee.bouche@simulations-plus.com
Hayden IR
Brian Siegel
brian@haydenir.com
Source: Simulations Plus, Inc.
Simulations Plus Inc.
NASDAQ:SLP
SLP Rankings
#3207 Ranked by Stock Gains
SLP Stock Data
Industry
Computer Systems Design Services
Sector
Professional, Scientific, and Technical Services
Tags
Technology Services, Packaged Software, Professional, Scientific, and Technical Services, Computer Systems Design Services
Country
US
City
Lancaster
About SLP
simulations plus, inc. (nasdaq: slp) is the premier developer of modeling & simulation software and consulting services supporting drug discovery, development research and regulatory submissions. we partner with companies to provide a data-driven, ‘strategic modeling methodology’, starting in early discovery, continuing through preclinical/clinical development, and concluding with clinical trials/post approval. with our subsidiaries, cognigen corporation and dilisym services, we offer #1-ranked, easy-to-use software (gastroplus™, admet predictor™, kiwi™, dilisym®, nafldsym®, pkplus™, and more) to bridge data mining, compound library screening with qsar models, pbpk/tk modeling & simulation in animals and humans following administration around the body, and quantitative systems pharmacology approaches. simulations plus technology is licensed to and used by regulatory agencies worldwide. for over 20 years, simulations plus has partnered with our clients to reduce costs and accelerate res
